# A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

> **NCT05918107** · PHASE2 · RECRUITING · sponsor: **Biotheus Inc.** · enrollment: 55 (estimated)

## Conditions studied

- MPM

## Interventions

- **DRUG:** PM8002
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05918107
- **Lead sponsor:** Biotheus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-13
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918107, "A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT05918107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*